Page 3 - Libre Sense News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Author Bio Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights Abbott Laboratories (NYSE:ABT) entered 2020 as a strong and growing business. Then the COVID-19 pandemic hit, and the company became even stronger, with much faster growth.  The healthcare giant announced its first-quarter results before the market opened on Tuesday. Here ar...

Alex Hogan/STAT For the 1.6 million people in America living with type 1 diabetes, a continuous glucose monitor can be a lifesaver. Since the first CGM was approved by the Food and Drug Administration in 1999, the diabetes community has advocated for lower prices and better insurance coverage for the quarter-sized devices, which regularly sample a proxy for blood glucose levels and can sound an alarm when they swing too high or too low. But the cost-cutting has had an unexpected side effect: Today, glucose monitors are so cheap they’ve spawned a new crop of digital health startups selling t...

World's Fastest Marathoner Eliud Kipchoge Uses Abbott's Libre Sense at NN Mission Marathon Qualifier Race for the Olympic Games - Abbott, Eliud Kipchoge and the NN Running Team collaborate in a partnership to track glucose levels during training and marathons - Kipchoge and NN Running Team members will wear Abbott's Libre Sense Glucose Sport Biosensor in upcoming competition at the NN Mission Marathon, the fastest way to the Tokyo Games - Built upon the company's world-leading continuous glucose monitoring technology,[i] Abbott's Libre Sense is the world's first glucose biosensor[ii] designed...